Month: January 2023

SPONSORED CONTENT

We are pleased to again bring you Visante’s Top 10 issues in pharmacy for 2023.

The American Hospital Association purchased a large ad in The Wall Street Journal print edition Tuesday touting the 340B program’s benefits and saying, “It is in the best interest of all to keep the 340B program strong.”

The quarter-page

An Ohio-based health system that was the focus of a New York Times investigation of alleged 340B program misuse opened a long-delayed medical office building this week near the Richmond, Va., hospital featured in the exposé.

Bon Secours Health System

The U.S. Centers for Medicare & Medicaid Services will publish the first 10 Medicare Part D drugs selected for the new Medicare Drug Price Negotiation Program by Sept. 1, CMS announced yesterday.

The negotiated maximum fair prices for these drugs

A federal district judge in Washington, D.C., this morning ruled that Medicare Part B underpayments to hospitals for 340B drugs from 2018 to 2022 were unlawful. But in a disappointment for the hospital groups that sued, the judge declined to

A federal district court in South Carolina ordered 340B Report late yesterday to destroy and not release information from more than 9,000 pages of documents that the federal government filed in a public database Thursday in a community health center’s

The members, GOP chairs, and top-ranking Democrats of U.S. House committees for the 118th Congress still had not been formally announced this morning, three days after Republicans chose Rep. Kevin McCarthy (R-Calif.) to be House speaker.

It took four days

The 340B program “is buckling under its own weight and overdue for reform,” biotechnology industry trade group BIO said last week in its blog.

BIO, which is marking its 30th anniversary in 2023, has experienced inner turmoil in recent

Federal Medicare officials plan to issue a proposed rule in April regarding “potential remedies” for illegal Part B drug payment cuts for 340B hospitals from 2018 through late September 2022.

The Centers for Medicare & Medicaid Services revealed April as

U.S. Sen. Debbie Stabenow (D-Mich.) will not seek re-election in 2024, a decision that will deprive 340B covered entities of a reliable ally in Congress.

Stabenow issued a statement yesterday announcing her decision. She was one of six senators—three